Cancer NetworkOriginal article
<![CDATA[FDA Receives sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis]]>
NDA FilingselinexorruxolitinibPositive
AI Analysis
Summary
FDA received a supplemental new drug application for selinexor plus ruxolitinib in myelofibrosis, supported by Phase 3 SENTRY trial data.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Supplemental new drug application received by FDA
Importance:7/10
Sentiment:
0.60
myelofibrosisselinexorruxolitinibsNDASENTRY trialPhase 3
Related Companies
Read the original article
Published by Cancer Network on September 1, 2026 3:00 PM